ROUNDUP 2: Nordkorea verkündet Aussetzung seiner Atom- und Raketentests

Q BioMed Drug Development Partner to Attend EANM 2016 in Barcelona, Spain October 15-19 2016

Dienstag, 18.10.2016 15:30 von PR Newswire

PR Newswire

NEW YORK, October 18, 2016 /PRNewswire/ --

Q BioMed Inc. (OTCQB: QBIO), Strontium Chloride 89 (SR89) drug development partner will attend the European Association of Nuclear Medicine (EANM) meeting in Barcelona, Spain.

With more than 130 Sessions, the EANM Annual Congress is the most valuable Nuclear Medicine Meeting worldwide. Each year, more than 5,500 participants have the possibility to network, socialize and discuss the newest trends and findings in the field of Nuclear Medicine. The EANM has approximately 2,100 abstracts annually from all over Europe and overseas. 130 exhibiting companies, covering an area of 3,000 sqm present their newest technologies.  

Members of the Q BioMed advisory group and technology partners will be meeting with industry colleagues, collaborators and manufactures of materials required for the scale up and production of Q BioMeds recently licensed, FDA approved, SR89 drug. This licensed radiopharmaceutical agent is indicated for the treatment of pain associated with metastatic bone cancer. SR89  provides long lasting relief for patients suffering from bone pain due to metastatic cancer, typically caused by advanced-stage breast, prostate or lung cancer. The drug is preferentially absorbed in bone metastases, it has been proven to provide a long-term effect resulting in non--narcotic cancer pain relief and enhanced quality of life.  

There are approximately 300,000 new cases of bone metastases in patients with breast and lung cancer per year in the U.S. alone.  Approximately 80% of patients using SR89 have reported experiencing a substantial decrease in pain, an increase in physical activity and a reduction in the need for opiate analgesics, such as morphine.

Q BioMed CEO, Denis Corin said, "Key raw materials required for the manufacturing of the drug are sourced from Europe and this meeting provides an ideal opportunity to meet with all the relevant suppliers and stakeholders. These relationships and the agreements that result from these meetings are an important milestone as we begin roll out of the manufacturing process."

We expect to update the market with details surrounding the strategic milestones related to the production and delivery of this drug to market once they are finalized.

Please visit our website to sign up for regular updates and stay up-to-date with our progress.

About Q BioMed Inc. 

Q BioMed Inc."Q" is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need.

Forward-Looking Statements: 

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Denis Corin
Q BioMed Inc.